ATB Therapeutics
PrivateLast Round
Series A
Nov 18, 2024
Total Funding Raised
$62.6M
Company Overview
ATB Therapeutics is a biotechnology company that develops a new class of antibody-based targeted therapies, called atbodies, to treat cancer and autoimmune diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
ATB Therapeutics Comps
Public and private peers based on sector, stage, and business model.
| Company | Status | Est. Valuation | Rev Multiple |
|---|---|---|---|
| OpenAI | Private | $86.0B | ~40x |
| Cohere | Private | $5.0B | -- |
| Competitor 1 | Public | $XX.XB | XXx |
| Competitor 2 | Public | $XX.XB | XXx |
ATB Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Nov 18, 2024 | ||||
| Seed | Dec 23, 2019 | ||||
| Seed | Jan 1, 2018 |
Key People
Founding team and executive leadership
ATB Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Federal Holding and Investment Company | Series A |
| EQT Life Sciences | Series A |
| Noshaq | Seed |
| Wallonie Entreprendre | Series A |
| V-Bio Ventures | Series A |
| VIVES Partners | Series A |
| Financière Spin-off Luxembourgeoise | Seed, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 18, 2024
Raised $57M in Series A funding.
- Dec 23, 2019
$4.3M round led by Fondation Fournier-Majoie and ORSA
ATB Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about ATB Therapeutics's valuation, stock price, and market status.